Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.

Autor: Klocker EV; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Austria., Hasenleithner S; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Austria., Bartsch R; Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria., Gampenrieder SP; Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Austria., Egle D; Department of Gynecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Austria., Singer CF; Department of Gynecology, Breast Cancer Center Vienna, Medical University of Vienna, Austria., Rinnerthaler G; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Austria., Hubalek M; Department of Gynecology, Breast Health Center Schwaz, Austria., Schmitz K; Institute of Pathology, University Medical Center Göttingen, Germany.; Tyrolpath Obrist Brunhuber GmbH and Krankenhaus St. Vinzenz, Zams, Austria., Bago-Horvath Z; Department of Pathology, Medical University Vienna, Austria., Petzer A; Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Barmherzige Schwestern, Elisabethinen, Ordensklinikum Linz GmbH, Austria., Heibl S; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Austria., Heitzer E; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Christian Doppler Laboratory for Liquid Biopsies for early Detection of Cancer, Medical University of Graz, Austria., Balic M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.; Division of Hematology and Medical Oncology, University of Pittsburgh School of Medicine, PA, USA., Gnant M; Comprehensive Cancer Center, Medical University of Vienna, Austria.
Jazyk: angličtina
Zdroj: Molecular oncology [Mol Oncol] 2024 Jun 12. Date of Electronic Publication: 2024 Jun 12.
DOI: 10.1002/1878-0261.13671
Abstrakt: The advancements in the detection and characterization of circulating tumor DNA (ctDNA) have revolutionized precision medicine and are likely to transform standard clinical practice. The non-invasive nature of this approach allows for molecular profiling of the entire tumor entity, while also enabling real-time monitoring of the effectiveness of cancer therapies as well as the identification of resistance mechanisms to guide targeted therapy. Although the field of ctDNA studies offers a wide range of applications, including in early disease, in this review we mainly focus on the role of ctDNA in the dynamic molecular characterization of unresectable locally advanced and metastatic BC (mBC). Here, we provide clinical practice guidance for the rapidly evolving field of molecular profiling of mBC, outlining the current landscape of liquid biopsy applications and how to choose the right ctDNA assay. Additionally, we underline the importance of exploring the clinical relevance of novel molecular alterations that potentially represent therapeutic targets in mBC, along with mutations where targeted therapy is already approved. Finally, we present a potential roadmap for integrating ctDNA analysis into clinical practice.
(© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Databáze: MEDLINE
Externí odkaz: